Flow Neuroscience is a Neuromodulation & Stimulation company founded in 2016 and based in London, United Kingdom. It has raised $9.3M in total funding, most recently a Series A in 2021.
| Date | Stage | Amount | Valuation | Lead investors |
|---|---|---|---|---|
| Aug 11, 2021 | Series A | $9.3M | — | Khosla Ventures |
At-home transcranial direct current stimulation (tDCS) device that delivers gentle electrical current to the prefrontal cortex to treat major depressive disorder, combined with a behavioral therapy app. FDA-cleared in December 2025 as the first non-drug, at-home device approved for depression treatment in the US. Previously available in Europe as a CE-marked Class IIa device since 2019 with 55,000+ units sold. Clinical trial showed 58% remission rate at 10 weeks, two to three times higher than sham treatment.
We don't have a live feed for this company's ATS. Their careers page has every open role.
View all careers ↗